Cisplatin and carboplatin--update
Geffen, D.B.; Cohen, Y.
Harefuah 129(3-4): 131-135
1995
ISSN/ISBN: 0017-7768 PMID: 8543240 Document Number: 451054
Document emailed within 1 workday
Related Documents
Skarlos, D.V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G.P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. 1997: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study Seminars in Oncology 24(5 Suppl 15: S15Fujita, Y.; Seki, N.; Inoue, K.; Miyazawa, T.; Eguchi, K. 2010: A comparison of cisplatin and carboplatin: a short review West Indian Medical Journal 59(1): 115
Adam, Z.; Mayer, J.; Hájek, R. 1994: Cisplatin and carboplatin in the treatment of malignant lymphoma and multiple myeloma Vnitrni Lekarstvi 40(12): 790-800
Willemse, P.H.; Blom van Assendelft, P.H.; Fontein, D.L.; Kloppenburg, M.; Boonstra, H.; de Vries, E.G. 1991: Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin Nederlands Tijdschrift Voor Geneeskunde 135(35): 1588-1592
Natale, R.B. 2003: Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer Oncology 17(7 Suppl. 7): 22-26
Lund, B.; Hansen, O.P.; Hansen, H.H.; Hansen, M. 1992: Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer Seminars in Oncology 19(1 Suppl 1: 26-29
Smith, I.E.; Harland, S.J.; Robinson, B.A.; Evans, B.D.; Goodhart, L.C.; Calvert, A.H.; Yarnold, J.; Glees, J.P.; Baker, J.; Ford, H.T. 1985: Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer Cancer Treatment Reports 69(1): 43-46
Elferink, F.; van der Vijgh, W.J.; Klein, I.; Pinedo, H.M. 1986: Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding Clinical Chemistry 32(4): 641-645
Hosaka, M.; Ebina, Y.; Moriwaki, M.; Hara, Y.; Araki, N.; Todo, Y.; Takeda, M.; Watari, H.; Sakuragi, N. 2007: Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(9): 1505-1508
Kiyama, Y.; Suzuki, G.; Masauzi, N.; Ohizumi, H.; Kobayashi, N.; Ogasawara, M.; Naohara, T.; Saito, M.; Higa, T.; Kasai, M. 1996: Two cases of relapse or refractory germ cell tumor who had been treated with combination chemotherapy of cisplatin and carboplatin Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(14): 1989-1992
Yoshimura, A.; Yamano, Y.; Gemma, A.; Yoshimori, K.; Hayashihara, K.; Taniguchi, Y.; Uematsu, K.; Shibuya, M.; Kudoh, S.; Niitani, H. 1993: An early phase Ii trial combining cisplatin and carboplatin in advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(4): 503-508
Iwasaki, K.; Komuro, Y.; Masumoto, N.; Asaoka, K.; Ishitani, K. 1999: A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(10): 1483-1486
Bosl, G.J.; Bajorin, D.F. 1994: Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison Seminars in Oncology 21(5 Suppl 12: 61-64
Gadducci, A.; Facchini, V.; Dell'Arciprete, T.; Del Bravo, B.; Galigani, P.; Palla, R.; Fioretti, P. 1988: Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin Minerva Ginecologica 40(1): 33-38
Shimoya, K.; Kunishige, I.; Okuno, Y.; Hayashi, S.; Komura, H.; Arimoto, Y.; Otsuki, Y. 2001: A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(6): 845-848
Coughlin, C.T.; Richmond, R.C. 1989: Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin Seminars in Oncology 16(4 Suppl 6: 31-43
Calvert, A.H.; Newell, D.R.; Gore, M.E. 1992: Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin? Seminars in Oncology 19(1 Suppl 2: 155-163
Olawaiye, A.B.; Godoy, H.E.; Shahzad, M.M.K.; Rauh-Hain, J.A.; Lele, S.B.; Odunsi, K. 2012: Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer European Journal of Gynaecological Oncology 33(5): 477-479
Vapattanawong, P. 2006: A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer Journal of the Medical Association of Thailand 89(9): 1357-1361
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30